Global intestinal pseudo obstruction treatment market is expected to grow with an impressive CAGR in the forecast period, 2023-2027 due to growing healthcare industry. Increasing instances of complexities in the diseases and its after effects, further drive the growth of the global intestinal pseudo obstruction treatment market in the upcoming five years.
Intestinal pseudo obstruction is a rare condition where muscle impairment causes disruption in the gastro-intestinal muscle contraction. Thus, movement of the food gets obstructed and cause various abnormalities. The disease is of two typesabnormalities of the gastrointestinal muscles themselves (myogenic) or problems with the nerves that control the muscle contractions (neurogenic). There is no real obstruction but the lacks of the human muscles and neurons that fail to function appropriately. Due to the condition of intestinal pseudo obstruction, partially digested food in the intestines gets accumulated that further causes abdominal swelling, pain, nausea, vomiting, and constipation or diarrhea. Patients often lose appetite or have difficulty in nutrient absorption that may lead to malnutrition in extreme conditions.
Gastro Intestinal Conditions Drive Market Growth
Rapidly increasing instances of various stomach disorders, indigestion severity, and other related gastro intestinal diseases are anticipated to drive the growth of the global intestinal pseudo obstruction treatment market in the upcoming five years. Increasing geriatric population is also responsible for the market growth since the instances of the disorder in older and adult population is higher in comparison to children population. ‘
The condition in children is usually congenital. But the adult population develop the conditions due to neural degeneration or muscle abnormalities. In the year 2019, the United States 22% of the adult population were diagnosed with the intestinal pseudo obstruction conditions. Thus, the demand for the treatment of the condition rapidly grew in the past years, and it is anticipated to grow in future five years too. Moreover, in 2017, male adult population of the United States accounting for over 10% confirm that they suffer from excruciating pain due to gastro intestinal conditions and require intestinal pseudo obstruction treatment in a year.
Technological Advancement Supports Market Growth
Increasing advancement and consistent research toward improvising the technologies, products, and treatment methods for the intestinal pseudo obstruction treatment further substantiate the growth of the global intestinal pseudo obstruction treatment market in the next five years. Non-specific clinical symptoms, strong heterogeneity, and no definitive cause in some patients make diagnosis of the conditions very difficult. Gastro intestinal imaging and manometry of the organ tract is commonly used to diagnose the conditions of intestinal pseudo obstructions.
Click here to download the sample
Market Segmentation
The global intestinal pseudo obstruction treatment market segmentation is based on condition, diagnosis, treatment, end user, regional distribution, and competitive landscape. Based on condition, the market is divided between acute and chronic conditions. On the basis of diagnosis, the market is further bifurcated into blood test, gastric emptying tests, imaging tests, and others. Based on treatment, the market segment is defined into medication, surgery, diet, and others. The market analysis based on end user, is differentiated into hospitals & clinics, ambulatory care centers, others.
Company Profile
Pfizer, Inc., Cipla Inc., GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Novartis AG, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Lupin Limited, are enlisted in a partial list of major market players of the global intestinal pseudo obstruction treatment market.
| Attribute | Details |
| Base Year | 2021 |
| Historical Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Condition · Diagnosis · Treatment · End User |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States, Mexico, Canada, China, India, Japan, South Korea, Australia, Germany, France, United Kingdom, Spain, Italy, South Africa, UAE, Saudi Arabia, Brazil, Argentina, Colombia. |
| Key companies profiled | Pfizer, Inc., Cipla Inc., GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Novartis AG, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Lupin Limited |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
